#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Trends in allogeneic haematopoietic cell transplantation – analysis of the activity of the transplant centre at the University Hospital Plzeň in the period 2001– 2021


Authors: A. Turková;  P. Jindra;  M. Karas;  D. Lysák;  K. Steinerová;  A. Jungová;  M. Hrabětová;  J. Šrámek;  L. Mohammadová;  T. Prochazka;  T. Dekojová;  V. Bergerová
Published in: Transfuze Hematol. dnes,31, 2025, No. 2, p. 97-102.
Category: Original Papers
doi: https://doi.org/10.48095/cctahd2025prolekare.cz13

Overview

Allogeneic haematopoietic cell transplantation has evolved both in terms of indications and procedural execution. We retrospectively evaluated this development in 855 patients who underwent consecutive transplantation between 2001 and 2021 by comparing three seven-year time periods: 2001–2007 (N = 257, period/cohort A), 2008–2014 (N = 304, period/cohort B), and 2015–2021 (N = 294, period/cohort C). Over the observed periods, there was a significant increase in the median age of patients – from 50 years (range 20–68) to 53 years (19–71) and then to 55 years (20–74); P < 0.0001. Similarly, the proportion of patients aged ≥ 70 years increased from 0 in cohort A to 23 (8%) in cohort C; P < 0.0001. This reflects a decline in the use of myeloablative conditioning regimens (43% in A compared to 24%/28% in B/C; P < 0.0001). There were significant changes in donor types, with an increase in haploidentical donors in period C: 27% compared to 1%/0% in B/A (P < 0.0001). At the same time, the proportion of matched sibling donors declined (from 41% to 26%, and then 9%; P < 0.0001), while the proportion of unrelated donors remained stable (60% vs. 73% vs. 64%). The use of bone marrow as a source of haematopoietic cells increased from 11% to 20% in cohort B (P = 0.0049) and then remained stable (18%; P = 0.943). Calcineurin inhibitor/metotrexate was the standard GVHD prophylaxis for all transplant types, except for haploidentical transplants, where post-transplant cyclophosphamide was exclusively used. The use of anti-thymocyte globulin increased significantly (from 22% to a recent 55%; P < 0.0001). Throughout all periods, myeloid malignancies (AML/MDS/MPN) remained the primary indication for transplantation, with their proportion steadily increasing (39% in A vs. 62% in C; P < 0.0001). In contrast, CML and CLL showed a significant decline (11%, 4%, and 1%; P < 0.0001, respectively 14%, 13%, and 3%; P < 0.0001). The proportions of other indications – ALL, NHL, MM, HL, MPN – remained stable with no significant fluctuations (e. g., ALL 9%, 13%, and 9%; P = 0.1608). This analysis highlights the trend towards transplanting increasingly older patients and the predominance of unrelated and haploidentical transplantations. Myeloid malignancies remain the dominant indication for transplantation.

Keywords:

donor – allogeneic stem cell transplantation – conditioning regimen – GvHD prophylaxis – source of hematopoietic stem cell


Sources
1. Singh AK, McGuirk JP. Allogeneic stem cell transplantation: a historical and scientific overview. Cancer Res. 2016; 76 (22): 6445–6451.
2. D’Souza A, Fretham C, Lee SJ, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020; 26 (8): e177–e182. doi: 10.1016/j.bbmt.2020.04.013
3. Gratwohl A, Baldomero H, Gratwohl M, et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica. 2013; 98 (8): 1282–1290.
4. Luznik L, O’Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012; 39 (6): 683–693.
5. Passweg JR, Baldomero H, Ciceri F, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplant. 2024; 59 (6): 803–812.
6. Passweg J, Baldomero H, Ciceri F, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplant. 2023; 58 (6): 647–658.
7. Muffly L, Pasquini MC, Martens M, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017; 130 (9): 1156–1164.
8. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. New Engl J Med. 2020; 383 (7): 617–629.
9. Cusatis R, Litovich C, Feng Z, et al. Current trends and outcomes in cellular therapy activity in the United States, including prospective patient-reported outcomes data collection in the Center for International Blood and Marrow Transplant Research Registry. Transplant Cell Ther. 2024; 30 (9): 917.e1–917.e12. doi: 10.1016/ j.jtct.2024.06.021.
10. Alousi A, Wang T, Hemmer MT, et al. Peripheral blood versus bone marrow from unrelated donors: Bone marrow allografts have improved long-term overall and graft-versus-host disease-free, relapse-free survival. Biol Blood Marrow Transplant. 2019; 25 (2): 270–278. doi: 10.1016/ j.bbmt.2018.09.004.
11. Lee SJ, Logan B, Westervelt P, et al. Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation. JAMA Oncol. 2016; 2 (12): 1583. doi: 10.1001/jamaoncol. 2016.2520.
12. Snowden JA, Sánchez-Ortega I, Corbacioglu S, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2022. Bone Marrow Transplant. 2022; 57 (8): 1217–1239. doi: 10.1038/s41409-022-01691-w.
PODÍL AUTORŮ NA PŘÍPRAVĚ RUKOPISU
AT – příprava rukopisu, psaní manuskriptu, finální editorství
PJ – koncept publikace, psaní manuskriptu, příprava grafů, revize a finální editorství
KS – léčba pacientů, statistická analýza dat
MK, DL, AJ, MH, JŠ, LM, TP, TD, VB – léčba pacientů
PROHLÁŠENÍ O STŘETU ZÁJMŮ
Autoři nemají ve vztahu k rukopisu žádný konflikt zájmů.
PODĚKOVÁNÍ (GRANTOVÁ PODPORA)
Podpořeno projektem institucionálního výzkumu MZČR – FNPl, 00669806.“
Do redakce doručeno dne: 3. 2. 2025.
Přijato po recenzi dne: 17. 2. 2025.
MUDr. Adéla Turková
Hematologicko-onkologické oddělení
FN Plzeň
Alej Svobody 923/80
32300 Plzeň 1
e-mail: turkovaa@fnplzen.cz
Labels
Haematology Internal medicine Clinical oncology

Article was published in

Transfusion and Haematology Today

Issue 2

2025 Issue 2

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#